首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Mitochondrial targeting nanodrugs self-assembled from 9-O-octadecyl substituted berberine derivative for cancer treatment by inducing mitochondrial apoptosis pathways
【24h】

Mitochondrial targeting nanodrugs self-assembled from 9-O-octadecyl substituted berberine derivative for cancer treatment by inducing mitochondrial apoptosis pathways

机译:通过诱导线粒体凋亡途径,从9-O-十八烷基取代的小檗碱衍生物自组装的线粒体靶向纳米粒子从9-O-十八烷基取代的小檗碱衍生物进行癌症治疗

获取原文
获取原文并翻译 | 示例
       

摘要

Mitochondria are ideal anti-tumor target due to mitochondria's central regulation role in cell apoptosis and tumor resistance to apoptosis. There are several challenges for mitochondrial targeting drug delivery, including complex multistep preparations, low drug-loading and systemic toxicity from the carriers. To address these issues, we firstly constructed mitochondria-targeting nanodrugs self-assembled from 9-O-octadecyl substituted berberine derivative (BD) using simple nano-precipitation approach. BD-based nanodrugs were modified by DSPE-PEG2000 (distearylphosphatidylethanolamine- methoxypolyethylene glycol 2000) to increase stability. Negatively charged hyaluronic acid (HA) was further coated to conceal positive charges and achieve tumor targeting. PEG and HA dually modified BD NDs (HA/PEG/BD NDs) were prepared with surface charge of -25.8 mV and high drug loading 70%. The degradation of HA by hyaluronidase (HAase) at tumor tissue allowed the exposure of the positively charged PEG/BD NDs to the cells, which is beneficial for cell uptake and further lysosome escape and mitochondrial targeting. Then, HA/PEG/BD NDs were investigated to induce apoptosis through dissipating mitochondria membrane potential, releasing cytochrome C, increasing the activities of caspase 9/3, activating the pro-apoptotic Bax, suppressing the anti-apoptotic Bcl-2 and upregulating ROS levels. In the A549 xenografted tumor model, HA/PEG/BD NDs exhibited obvious tumor cell mitochondrial targeting and significant anti-tumor efficacy. Overall, comparing to conventional nanoparticles, mitochondrial targeting HA/PEG/BD NDs provide a new strategy for cancer treatment with enhanced drug-loading, relatively simplified preparation processes and reduced carrier toxicities.
机译:线粒体是由于线粒体中的抗肿瘤靶标是细胞凋亡和肿瘤凋亡中的细胞凋亡和肿瘤抗性。线粒体靶向药物递送存在若干挑战,包括来自载体的复杂多体制剂,低药物载荷和全身毒性。为了解决这些问题,我们首先使用简单的纳米沉淀方法构建了从9-O-十八烷基取代的小檗碱衍生物(BD)自组装的线粒体靶向纳米树脂。通过DSPE-PEG2000(Distearylylylylylylylidylidylamine-甲氧基聚甲氧二甲基二甘醇2000)改性Bd基纳米醇溶蛋白以增加稳定性。带负电荷的透明质酸(HA)进一步涂覆以隐藏正电荷并实现肿瘤靶向。用表面电荷为-25.8mV和高药物负荷,制备PEG和HA双重修饰的BD NDS(HA / PEG / BD NDS)。 70%。肿瘤组织透明质酸酶(HA酶)的降解HA通过肿瘤组织允许带正电荷的PEG / BD NDS暴露于细胞,这对于细胞吸收和进一步的溶酶体逸出和线粒体靶向是有益的。然后,研究了HA / PEG / BD NDS通过散发线粒体膜电位,释放细胞色素C,增加Caspase 9/3的活性,激活促凋亡Bax,抑制抗凋亡Bcl-2和上调ROS的活性,并抑制抗凋亡Bcl-2和上调ROS的活性水平。在A549异种移植的肿瘤模型中,HA / PEG / BD NDS表现出明显的肿瘤细胞线粒体靶向和显着的抗肿瘤疗效。总体而言,与常规纳米颗粒相比,线粒体靶向HA / PEG / BD NDS为具有增强的药物负载,相对简化的制备方法和降低的载体毒性提供了一种新的癌症治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号